Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05958082 · ClinicalTrials.gov registry record · NA
Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
A NA study of Prostate Cancer, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05958082: Recruiting NA study of Prostate Cancer, sponsored by Henry Ford Health System.
NCT05958082 is a NA study of Prostate Cancer that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 50 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05958082, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
Primary Outcome
percentage of patients who undergo genetic testing after completing the education session
Conditions Studied
Interventions
- BEHAVIORAL Educational video
Study Locations (1)
Michigan
- Henry Ford Cancer Pavilion - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05958082 shows while recruiting
NCT05958082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Educational video is the first listed.
NCT05958082 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05958082 about?
NCT05958082 is a clinical study titled "Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer". This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an ed...
What is the current status of trial NCT05958082?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-01-01. Estimated completion is 2026-12.
What conditions does trial NCT05958082 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05958082?
The interventions under investigation include: Educational video (BEHAVIORAL).
Who is sponsoring clinical trial NCT05958082?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05958082 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05958082's enrollment target sits among peer trials
50 469th of 735 higher than 247 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI